TCT-726 Characteristics and outcomes of clopidogrel responder and hypo-responder patients post transcatheter aortic vavle replacement  by Asher, Elad et al.
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PM
P
O
S
T
E
R
STCT-723
What Should The Default Vascular Access And Closure Strategy Be For
Transcatheter Aortic Valve Replacement?
Sa'ar Minha1, Marco A. Magalhaes2, Israel Barbash1, Itsik Ben Dor1,
Petros Okubagzi3, Salem Badr1, Hironori Kitabata1, Joshua P. Loh1, Alfazir Omar4,
Hideaki Ota5, lakshmana Pendyala1, Fang Chen1, Augusto Pichard1,
Lowell F. Satler1, William O. Suddath1, Kenneth Kent1, Rebecca Torguson6,
Ron Waksman1
1Medstar Washington Hospital Center, Washington, DC, 2MedStar Washington
Hospital Center, Washington, DC, 3Washington Hospital Center, Washington, DC,
4Medstat Washington Hospital Center, Washington, DC, 5Medstar Washington
Hospital Center, Washington , DC, 6Medstar Washington Hospital Center,
Washington, DC
Background: Transcatheter aortic valve replacement (TAVR) success is hampered by
a relatively high rate of vascular complications, which correlates with mortality. A
trend from surgical access to percutaneous has led to a decrease in the reported
complication rate, but it is still considered a valid access strategy. The aim of this
study was to explore the vascular complication rates of surgical versus percutaneous
access for TAVR and of the two most frequently used closure devices.
Methods: From a cohort of 231 patients who underwent transfemoral TAVR, 38
(16.5%) had planned surgical access while 193 (83.5%) had percutaneous access
(Perclose ProGlide n¼160; ProStar n¼33). A comparison of the three groups’ baseline
characteristics, Valve Academic Research Consortium (VARC)-deﬁned vascular
complication, and mortality rates was performed.
Results: Baseline characteristics were mostly similar save for a higher incidence of
SAPIEN valve use in the surgical access group (71.3% percutaneous vs. 97.4%
surgical; p <0.001). Although the rate of major VARC vascular complication did not
differ between groups, (Figure) access site hematomas, major bleeding and need for
transfusion were more frequent in the surgical access group. Mortality rates at 30 days
and 1 year did not differ among the three groups. No differences were noted in
outcome when Perclose was compared with Prostar use.
Conclusions: Complete percutaneous vascular access and closure with either Perclose
ProGlide or ProStar is associated with lower rates of vascular complications compared
with surgical cut down and should be the preferred access technique in TAVR.TCT-724
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Background: It may be challenging to distinguish low-ﬂow low-gradient (LFLG)
severe aortic stenosis (AS) from pseudo-severe AS, underestimation normal-ﬂow
high-gradient (NFHG) AS, or inaccurate effective oriﬁce area (EOA) on transthoracic
echocardiography (TTE). We evaluated changes in classiﬁcation of AS by left/right
heart catheterization (LHC) over TTE ﬁndings alone.
Methods: We examined 144 consecutive individuals with severe AS on TTE (EOA
<1.0 cm2 or indexed EOA <0.6 cm2/m2) and LHC within 2 months referred for
possible transcatheter aortic valve implantation (TAVI), and after exclusion of patients
with >mild tricuspid regurgitation (n¼27), subaortic obstruction (n¼3) or non-diag-
nostic studies (n¼6). We evaluated the prevalence and hemodynamic ﬁndings of
NFHG (mean gradient >40 mmHg or peak velocity >4.0 m/sec) and LFLG severe AS
on TTE (mean gradient 40 mmHg and peak velocity 4.0 m/sec), and assessed the
frequency in which LHC reclassiﬁed AS type.
Results: Mean age was 78.98.8 years, and 58.3% were male. TTE observed a high
mean gradient in 36% (52/144) of patients, while a high peak velocity was noted in
44% (63/144). LHC observed a high gradient in 59% (85/144) of individuals. Overall,
TTE identiﬁed NFHG and potential LFLG severe AS in 46% (66/144) and 54% (78/
144) of patients, respectively. In the 78 patients with potential LFLG severe AS by
TTE, LHC reported a mean gradient >40 mmHg in 41% (32/78), consistent with TTEJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrunderestimation of gradients; in an additional 10% (8/78), LHC reported an EOA
1.0 cm2, suggesting overestimation of AS severity on TTE. In comparison to TTE
alone, the addition of LHC ﬁndings reduced the proportion of patients with potential
LFLG severe AS from 54% (78/144) to 26% (38/144)(p<0.001), while LHC
conﬁrmed the presence of severe AS in 94% (136/144) of patients.
Conclusions: TTE reporting of LFLG severe AS is common in patients referred for
TAVI. The addition of LHC hemodynamics reclassiﬁed about half of LFLG cases by
TTE as having NFHG severe AS, although LHC agreed with the overall diagnosis of
severe AS in 94% of cases. In patients with LFLG severe AS by TTE, LHC may be
useful to conﬁrm this diagnosis.
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Background: TAVI represents an emerging technology that is nowadays widely used
for the treatment of aortic-valve disease in high-risk patients. However, paravalvular
leakage (PVL) still represents a major problem and was recently shown to be associated
with increased mortality and morbidity. This study evaluates the impact of CT based
aortic-valve calciﬁcation and its distribution on the post-procedural occurrence of PVL.
Methods: From May 2008 to December 2012 a total of 369 patients were scheduled
for the treatment of aortic stenosis with a TAVI procedure either using a CoreValve-
Medtronic (n¼198), Edwards-SAPIEN (n¼164), Symetis-Acurate (n¼2) and
Medtronic-Engager prosthesis (n¼5). Of these, 260 patients with a mean logistic
EuroSCORE I of 19.312% had a preoperative CT-Scan and were included in this
study. AVCS was measured in mg and mm3 using a method analogous to the
Agatston calcium scoring of coronary arteries. The image data were analyzed sepa-
rately to determine the degree of calciﬁcation for each cusp and commissure. The
occurrence of intra- or post-procedural PVL was assessed by echocardiography and
correlated to the calcium degree and distribution.
Results: TAVI was successfully performed in 254 Patients (97.7%). A new Pacemaker
Implantation was observed in 22.4% (n¼57) of patients and MACE (Myocardial
Infarction, Stroke, major vascular complication, Death) occurred in 11.4% (n¼29) of all
cases. The mean hospital length of stay was 11.3  8.3 days. There was a statistically
relevant difference inAVCSbetweenGroupswhen correlating to the occurrence of post-
interventional PVLGrade*0-1 (550.4 377.2 mg, n¼164) and Grade 2 (755.6 470.6
mg, n¼78, p<0.001) or Grade 3 (825  460.8 mg, n¼12, p<0.05). There was no
correlation between a new pacemaker implantation and AVCS.
Conclusions: This study highlights the signiﬁcant correlation between the degree of
calciﬁcation and the occurrence of post-interventional paravalvular leakage after
TAVI procedure. Thus, preoperative AVCS calculation may represents an important
predictor for PVL and may be added to the routine list of parameters for CT planning
before TAVI. *PVL Grade 0 - none; 1 - minimal; 2 - mild; 3 – moderate
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Background: Dual anti-platelet therapy is an essential component of post- percuta-
neous coronary intervention (PCI) and transcatheter aortic valve replacement (TAVR)
management. While several trials have studied the impact of hypo-responsiveness to
clopidogrel [Platelet Reactivity Units (PRU) > 230] in PCI patients, data on the
clopidgorel hypo-responsiveness post TAVR is lacking. The objectives of the study
were to characterize predictors and outcomes of clopidogrel responders and hypo-
responders patients using Accumetrics VerifyNow (San Diego, CA) P2Y12 testing
post TAVR.
Methods: Twenty two consecutive patients underwent TAVR and platelet function
testing after initial background aspirin and 600 mg of clopidogrel. Post procedure
a daily maintenance dose of 75 mg clopidogrel was administrated. Patients' charac-
teristics, presentation [heart failure, syncope, angina] and major adverse cardiac events
(MACE) (death, acute myocardial infarction, major bleeding and re-admission) were
compared between responders and hypo-responders.
Results: Of the 22 patients 15 (68%) were hypo-responders. Comparison between the
two groups is presented in table 1. MACE rate at 30 days was similar between
responders and hypo-responders [2/7 (29%) vs. 3/15 (20%), respectively, p¼0.9)].acts/POSTER/Aortic Valve Disease and Treatment B221
Table 1. Comparison of patients characteristics between both groups
Variable
Hypo-responders
N=15 (68%)
Responders
N=7 (32%) P value
Age (years) 84.17.4 76.817 0.08
Gender (Men) 11 (73%) 2 (29%) 0.07
Body Mass Index 30.15.9 24.25.4 0.01
HTN 15 (100%) 7 (100%) 1
DM 8 (40%) 6 (86%) 0.19
Dyslipidemia 14 (93%) 3 (43%) 0.02
Prior Smoker 8 (53%) 3 (43%) 0.9
Prior MI 4 (27%) 2 (29%) 1
Admission with
CHF
14 (93%) 6 (86%) 0.9
Troponin I (ng/ml) 3.68  3.13 0.05  0.04 0.04
Cholesterol (mg/dl) 117.7  15.7 88.5  14.8 0.03
Hg (g/dl) 9.87  1.4 9.57  1.6 0.3
PLT (K/ul) 159  43.9 172  68.9 0.3
Creatinine (mg/dl) 1.75  1.9 1.73 1.6 0.5
HTN- Hypertension; DM- Diabetes Mellitus; MI- Myocardial infarction; CHF- Congestive heart
failure; CK- Creatine kinase; Hg- hemoglobin; PLT- platelets
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SConclusions: Clopidogrel hypo-responsiveness post TAVR is a very common
phenomenon. These patients are characterized by higher BMI, dyslipidemia and
a trend towards older age and male gender. MACE rate at 30 days was similar for
responders and hypo-responders. Further studies are needed to investigate this high
rate of hypo-responsiveness post TAVR and its potential consequences on clinical
outcomes.
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Background: Coronary artery disease (CAD) and aortic stenosis (AS) frequently
coexist. It remains unknown whether CAD severity exerts a gradient of risk in patients
with AS undergoing transcatheter aortic valve implantation (TAVI).
Methods: A total of 445 patients with severe AS undergoing TAVI were included into
a prospective registry between 2007 and 2012. The preoperative SYNTAX-score (SS)
was determined from baseline coronary angiograms. In case of revascularization prior
to TAVI, residual SS (rSS) was also determined. Clinical outcomes were compared
between patients without CAD (N¼158), patients with low SS (0-22, N¼207), and
patients with high SS (SS>22, N¼80). The prespeciﬁed primary endpoint was the
composite of cardiovascular death, stroke, or myocardial infarction (MI).
Results: At one year, CAD severity was associated with higher rates of the primary
endpoint (noCAD: 12.5%, low SS: 16.1%, high SS: 29.6%; p¼0.016). This was driven by
differences in cardiovascular death (no CAD: 8.6%, low SS: 13.6%, high SS: 20.4%;
p¼0.029), whereas the risk of stroke (no CAD: 5.1%, low SS: 3.3%, high SS: 6.7%;
p¼0.79) andMI (noCAD:1.5%, lowSS: 1.1%, highSS: 4.0%; p¼0.54)was similar across
the threegroups.Patientswith highSS received less complete revascularization as indicated
by a higher rSS (21.212.0vs. 4.04.4, p<0.001) comparedwith patientswith lowSS.Of
note, the highest rSS tertile (rSS>14) was associated with higher rates of the primary
endpoint at 1 year (no CAD: 12.5%, low rSS: 16.5%, high rSS: 26.3%, p¼0.043).
Conclusions: CAD is present in two-thirds of elderly patients with severe AS
undergoing TAVI in routine clinical practice. Severity of CAD appears to be asso-
ciated with impaired clinical outcomes at 1 year after TAVI. Patients with SS>22
receive less complete revascularization and have a higher risk of cardiovascular death,
stroke, or MI as compared to patients without CAD or low SS.
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Background: Right ventricular (RV) function is reduced after surgical aortic valve
replacement (sAVR). The long-term effect on RV function following transcatheterB222 JACC Vol 62/18/Suppl B j October 27–Novemberaortic valve implantation (TAVI) is less well established. The aim of this study was to
determine whether TAVI may preserve RV function at medium-term outcome.
Methods: We studied 79 consecutive patients (aged 837 years) with severe AS but
no ﬂow-limiting coronary artery disease, one week before and 12 months after
transfemoral TAVI with CoreValve. The TAVI group was compared with 36 patients
(aged 703 years) who underwent sAVR for severe aortic stenosis (AS). RV inlet
diameter measurement was averaged from apical 4-chamber and modiﬁed parasternal
windows, and tricuspid annular plain systolic excursion (TAPSE) was measured as the
M-mode displacement of the tricuspid ring between the q wave of the ECG to
pulmonary valve closure.
Results: The sAVR and TAVI groups had similar AS severity pre-operatively (mean
aortic pressure drop 5117mmHg vs. 4915mmHg respectively, and valve area
0.7cm2 vs 0.6cm2, p¼NS for both), though LVEF was reduced in TAVI patients
(657% vs. 4916%, p<0.001). There was no difference in RV size (353mm vs.
336mm), though TAPSE was greater in sAVR group (205mm vs. 156mm,
p<0.001). At 12 months, mean aortic pressure drop decreased and aortic valve area
increased in both sAVR and TAVI (to 103mmHg and 82mmHg respectively, and
to 2.00.3cm2 vs. 1.80.2cm2, p<0.01 for both), though LVEF did not change
(629% vs. 4917%). Although RV cavity size did not change in either group,
TAPSE decreased after sAVR (to 93mm) and increased after TAVI (174mm,
difference p<0.001).
Conclusions: At medium-term follow-up, RV function deteriorates after sAVR but
does not worsen after transfemoral TAVI. Therefore, patients with AS and pre-
existing RV dysfunction may beneﬁt preferentially from TAVI. Though clinical
signiﬁcance remains to be determined, RV function should be incorporated into risk
score pre-procedure.
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Background: Gait speed (GS) is an independent predictor of mortality after cardiac
surgery, however association with clinical outcomes in patients with severe aortic
stenosis (AS) undergoing surgical aortic valve replacement (SAVR) versus trans-
catheter AVR (TAVR) are limited.
Methods: From 3/2011-12/2012, all patients with severe AS evaluated by a multi-
disciplinary heart team underwent standardized GS testing with the 5 meter walk test.
Operative outcomes were assessed based on GS as both a continuous (m/s) and
categorical (normal/slow) variable with immobile patients assigned a GS of 0 m/s. The
primary end points were 30 day and one year mortality.
Results: We enrolled 285 patients (SAVR¼76, TAVR¼209). The optimal cutoff to
discriminate slow from normal GS was 0.7 m/s (6.9s/5m). Patients with normal GS
had a higher survival at one year(Figure). Overall normal GS was an independent
predictor of mortality at 30 days (OR 0.31,95% CI 0.11-0.88;p¼0.028) and one year
(OR 0.34 ,95% CI 0.12-0.99;p¼0.048) with an 11% reduction in 30 day mortality for
every 0.1m/s increase in walk speed. For one year mortality the STS PROM had an
AUC¼0.681, increasing to 0.704 with GS added. GS was an independent predictor of
30 day mortality after TAVR but not SAVR; with no signiﬁcant association with
mortality in the individual groups at one year.
Conclusions: GS is an independent predictor of mortality in patients with severe AS
undergoing therapy including TAVR, but adds minimal additional predictive infor-
mation to the STS risk score. Patients with slow GS or immobility should be carefully
evaluated and counseled regarding mortality risk.1, 2013 j TCT Abstracts/POSTER/Aortic Valve Disease and Treatment
